Takeda Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Takeda Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Takeda Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Takeda Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Takeda Pharmaceutical Co Ltd (Takeda) is a pharmaceutical company primarily engaged in the research, development, production, and commercialization of biopharmaceutical products. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. While the company markets its pharmaceutical products directly, it also collaborates with marketing alliance partners in worldwide. Takeda operates in various countries worldwide, including Japan, the US, Europe, Latin America, Africa, the Middle East and the Asia Pacific region. Takeda is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
1-1, Nihonbashi-Honcho 2-chome, Chuo-Ku, Tokyo, 103-8668
Website
www.takeda.com/jp
Telephone
81 3 32782111
No of Employees
47,029
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4502 (TYO)
Revenue (2025)
$29.0B
-1.7%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-241.2%
(2025 vs 2024)
Market Cap*
$50.7B
Net Profit Margin (2025)
XYZ
-243.2%
(2025 vs 2024)
* As of and is in US$
Takeda Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Therapy Areas: | Actos |
| Oncology | Blopress |
| Gastroenterology | Takepron |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In April, the company entered into an agreement to sell global rights to TAK-063 to Axsome Therapeutics, Inc. |
| 2026 | Contracts/Agreements | In January, the company entered into an agreement with Halozyme Therapeutics, Inc. for access to Halozyme’s ENHANZE drug delivery technology for use with vedolizumab. |
| 2026 | New Products/Services | In January, the company launched the GAMMAGARD LIQUID ERC in the US. |
Competitor Comparison
| Key Parameters | Takeda Pharmaceutical Co Ltd | The Procter & Gamble Co | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | Japan | United States of America | United States of America | United States of America | United States of America |
| City | Chuo-Ku | Cincinnati | Indianapolis | Rahway | New York City |
| State/Province | Tokyo | Ohio | Indiana | New Jersey | New York |
| No. of Employees | 47,029 | 109,000 | 50,605 | 75,000 | 75,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Julie Kim | President; Chief Executive Officer; Director | Executive Board | 2026 | - |
| Milano Furuta | Chief Financial Officer; Director | Executive Board | 2024 | 48 |
| Gabriele Ricci | Chief Data Officer; Chief Technology Officer | Senior Management | 2022 | 48 |
| Takako Ohyabu | Chief Sustainability Officer; Chief Corporate Affairs Officer | Senior Management | 2019 | 47 |
| Mwana Lugogo | Chief Ethics Officer; Chief Compliance Officer | Senior Management | 2019 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer